ASCO 2025: Alcohol-fueled cancer deaths are on the rise in the US
Reports and Proceedings
Updates every hour. Last Updated: 8-Jul-2025 16:10 ET (8-Jul-2025 20:10 GMT/UTC)
A new study led by experts at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, is the first to look at trends over time in alcohol-linked cancer mortality across the United States. The findings, titled “Escalating Impact of Alcohol-Related Cancer Mortality in the U.S.: A call for action,” will be presented May 31 at ASCO 2025.
A study led by University of Cincinnati Cancer Center researchers sheds new light on the mechanisms by which a major oncogene promotes and sustains lymphoma development and progression, paving the way for novel targeted therapies.
A team of researchers from MSK and Weill Cornell Medicine is expanding the understanding of how a decades-old treatment for bladder cancer works — an understanding that could help improve the effectiveness of immunotherapies more broadly.
More than three decades ago, the U.S. Food and Drug Administration (FDA) approved Bacillus Calmette-Guérin (BCG) as the first immunotherapy against cancer. And it is still used today to treat early-stage bladder cancer.
Now, a team of researchers from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center (MSK) and is expanding the understanding of how the treatment works — an understanding that could help improve the effectiveness of immunotherapies more broadly.